logo-loader
Orgenesis

HekaBio CEO says Orgenesis taken 'great steps' to solve biotech manufacturing cost problem

HekaBio CEO Robert Claar sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. 

The Japan based company targets innovations in oncology, autoimmune/inflammation and neurodegenerative disease that have a high potential for significant therapeutic benefit and healthcare cost savings.

Quick facts: Orgenesis

Price: $4.32

Market: NASDAQ
Market Cap: $69.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orgenesis gets Orphan Drug designation to treat severe diabetes

Orgenesis Inc (NASDAQ:ORGS) Chief Scientific Officer Dr. Sarah Ferber tells Proactive Investors the FDA has granted Orphan Drug designation to its Autologous Insulin Producing (AIP) cells as a cell-replacement therapy for the treatment of severe diabetes following a pancreatectomy, a surgical...

on 06/28/2019

2 min read